AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

11:14am EST
Change (% chg)

-2.00p (-0.05%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for AZN.L


AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal. Its medicines include Crestor for... (more)


Beta: 0.73
Market Cap(Mil.): £50,509.40
Shares Outstanding(Mil.): 1,264.16
Dividend: 131.00
Yield (%): 4.70


  AZN.L Industry Sector
P/E (TTM): 25.98 31.23 37.84
EPS (TTM): 1.54 -- --
ROI: 6.54 14.70 14.08
ROE: 14.82 15.24 14.83
Search Stocks

AstraZeneca CEO open for deals that pay from day one

LONDON, Feb 4 After a three-year rebuild, Chief Executive Pascal Soriot reckons AstraZeneca's drug pipeline is now "full", but he's still hungry for acquisitions that pay for themselves straight away.

04 Feb 2016

AstraZeneca warns on profits in 2016 as Crestor patent loss weighs

LONDON AstraZeneca warned on Thursday that revenue and earnings would drop this year due to the arrival of cheap generic rivals to Crestor, its top-selling cholesterol drug, which will offset growth in sales of newer medicines.

04 Feb 2016

UPDATE 3-AstraZeneca warns on profits in 2016 as Crestor patent loss weighs

* Q4 revenue $6.40 billion vs consensus $6.29 billion (Adds details on management incentives, further reaction)

04 Feb 2016

BUZZ-AstraZeneca: bottom of FTSE after tepid 2016 forecast

** AstraZeneca down over 3 pct, top FTSE 100 loser after drugmaker warns of a low to mid single-digit pct decline in 2016 rev, core EPS

04 Feb 2016

AstraZeneca sees fall in 2016 earnings as Crestor loss weighs

LONDON, Feb 4 AstraZeneca expects a low to mid single-digit percentage decline in earnings in 2016 as the arrival of cheap generic copies of cholesterol fighter Crestor offsets growth in sales of new medicines, the British-based drugmaker said on Thursday.

04 Feb 2016

BRIEF-AstraZeneca and Incyte announce lung cancer clinical trial collaboration

* AstraZeneca and Incyte announce new lung cancer clinical trial collaboration

11 Jan 2016

BRIEF-Astrazeneca says ties up with Moderna to co-develop immuno-oncology mRNA

* Co and Moderna Therapeutics announce new collaboration to co-develop and co-commercialise immuno-oncology mRNA Therapeutics

11 Jan 2016

BRIEF-AstraZeneca proposes to appoint PWC as external auditor

* Proposal to appoint PriceWaterhouseCoopers LLP as its external auditor for financial year ending Dec. 31, 2017 Source text for Eikon: Further company coverage:

23 Dec 2015

BRIEF-EU Medicines Agency recommends approval of AstraZeneca's gout drug

* Recommends granting a conditional marketing authorisation for AstraZeneca's lung cancer drug Osimertinib

18 Dec 2015

AstraZeneca buys most of Acerta for $4 billion to add cancer drug

LONDON AstraZeneca is to buy 55 percent of privately held biotech firm Acerta Pharma for $4 billion to give it access to a new kind of blood cancer drug, boosting its long-term growth at the cost of a near-term hit to earnings. | Video

17 Dec 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
Provider : New Constructs, LLC
Provider : Thomson Reuters Stock Report
Provider : ValuEngine, Inc.
Provider : S&P Capital IQ – STARS Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks